Our mission is to develop best in class, clinically supported healthcare and nutritional products for consumers and partners worldwide

For over 20 years we have researched the human microbiome, to develop a unique portfolio of native human strains that has been recognized as exceptional by leading scientists and clinicians. 

We are applying this to innovative products and ingredients in disease areas such as:

  • Gastrointestinal Health: PB continues to build and support its position in gut health and further advance our science in IBS and related conditions.

  • Stress & Sleep: with recent advances and interest in the gut-brain axis, supported by our discovery of the 1714-Serenitas® strain, PB is focused on the development of further evidenced based probiotics for the management of stress, stress-related fatigue, cognition and learning.

  • Metabolic health: PB is investigating applications of bacterial strains in metabolic conditions and liver health, including fatty liver disease.

We are also developing unique products targeting key life stages, including

  • Pregnancy & early Life: building on new research about the importance of appropriate microbiome seeding of new born babies and the impact on later life, we are studying interventions with well characterised strains for mum and baby to set a child's future health on the right path.

  • Healthy Aging: knowledge is growing on the role of inflammation in aging and of the gut-brain axis on cognition. PB is researching the impact that selected strains have on these key processes.

Products for healthcare professionals and consumers:

The PrecisionBiotics Group commercialises its probiotic strains for healthcare professionals and consumers.



, with 35624® culture, reduces any and all of the cardinal symptoms of Irritable Bowel Syndrome (IBS). It is now the No 1 recommended probiotic by US Gastroenterologists and Doctors*.

  • The 35624® culture has been shown in 2 landmark clinical trials** and over 80 publications to reduce any and all of the following symptoms:

    - Bloating & gas
    - Abdominal pain
    - Unpredictable diarrhoea and constipation

The 35624® culture is currently commercialised as a food supplement known as Alflorex in over 15 countries in Europe and Latin America and as Align® by our partner P&G in North America and Australia.



®, with the 1714-Serenitas® culture is one of the most exciting discoveries in the gut-brain arena. With growing interest in the potential of the gut-brain axis and 'psychobiotics', the 1714® culture has demonstrated ground breaking clinical activity*** and safety.

  • We have an exciting R&D program underway to explore the full potential of this unique strain.

  • It is currently commercialised as a food supplement in Europe, Zenflore.

Key research partners:

Our research partners include many of the world's leading centres of microbiome expertise. We are a foundation Industry Partner of APC Microbiome Ireland in University College Cork, Ireland.
We collaborate with more than 20 research institutions and clinics globally. Many of our partners have conducted ground breaking research using our strains, that include demonstrating

  • the ability of a probiotic to manage IBS symptoms, proven with our 35624® strain

  • the activation by a probiotic of the brain’s coping centres, with our 1714-Serenitas® strain.

With our research partners, we undertake both pre-clinical research (laboratory based research) and clinical research to provide rigorous clinical validation of our strains efficacy, safety and stability. 


Other Key Facts:

Headquarters: Cork, Ireland

Patents: over 230 patents, across multiple probiotic strains and markets

Markets: our probiotic strains are sold in more than 30 markets

Distributors: see here for more information on our distribution partners: Distributors

For more information, please contact us

*Among gastroenterologists who recommended a brand of probiotic in AlphaImpactRx 2008–2017 surveys. Among doctors who recommended a brand of probiotic in AlphaImpactRx 2017 survey.

**1. O’Mahony, L., McCarthy, J., Kelly, P., Hurley, G., Luo, F., Chen, K., O’Sullivan, G., Kiely, B., Collins, J., Shanahan, F. & Quigley, E. (2005). Gastroenterology 128, 541-551.

**2. Whorwell, P., Altringer, L., Morel, J., Bond, Y., Charbonneau, D., O’Mahony, L., Kiely, B., Shanahan, F. & Quigley, E. (2006). American Journal of Gastroenterology, 101, 1581-1590.

*** 1.Bifidobacterium longum 1714 as a translational psychobiotic: modulation of stress, electrophysiology and neurocognitive in healthy volunteers. Allen et al., Transl Psychiatry, 2016.      

***2. Wang et al. (2019). Bifidobacterium longum 1714™Strain Modulates Brain Activity of Healthy Volunteers During Social Stress. American Journal of Gastroenterology 00:1–11. https://doi.org/10.14309/ajg.0000000000000203